Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Ian N BruceRonald F Van VollenhovenKonstantina PsachouliaCatharina LindholmEmmanuelle MahoRaj TummalaPublished in: Lupus science & medicine (2023)
Anifrolumab treatment was associated with sustained improvements in overall SLE disease activity and skin responses versus placebo from Week 8, which likely led to greater glucocorticoid reductions in the anifrolumab versus placebo groups from Week 20. These findings provide insights to physicians and patients on when to expect potential clinical responses following anifrolumab treatment.
Keyphrases
- disease activity
- phase iii
- systemic lupus erythematosus
- rheumatoid arthritis
- placebo controlled
- clinical trial
- open label
- double blind
- end stage renal disease
- ankylosing spondylitis
- rheumatoid arthritis patients
- primary care
- newly diagnosed
- juvenile idiopathic arthritis
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- phase ii
- electronic health record
- big data
- climate change
- risk assessment